Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Toxicity testing

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44347   clinical trials with a EudraCT protocol, of which   7375   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    476 result(s) found for: Toxicity testing. Displaying page 1 of 24.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2019-004003-12 Sponsor Protocol Number: FluorouracilCapecitabine001 Start Date*: 2020-01-14
    Sponsor Name:Jessa Hospital
    Full Title: Implementation of pre-emptive geno- and phenotyping in 5-FU- or capecitabine-treated patients with the aim of reducing toxicity
    Medical condition: Gastro-intestinal cancers: stomach, pancreas, colon, rectum, anal tumors, esophagus
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-003617-18 Sponsor Protocol Number: 1439A-028 Start Date*: 2016-01-26
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: Phase IIb, Double-Blinded, Multicenter, Randomized Study to Assess the Effect on Central Nervous System (CNS) Toxicity of Switching from ATRIPLA™ (Efavirenz, Tenofovir, Emtricitabine) to MK-1439A ...
    Medical condition: Human Immunodeficiency Virus-1 infection
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10020161 HIV infection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) IE (Completed)
    Trial results: View results
    EudraCT Number: 2016-000833-40 Sponsor Protocol Number: CCR4502 Start Date*: 2016-10-07
    Sponsor Name:The Institute of Cancer Research
    Full Title: Phase I ’run in’ study followed by randomised phase II trial testing intra-tumoural hydrogen peroxide as a radiation sensitizer in patients with locally advanced/recurrent breast cancer in terms of...
    Medical condition: Women with locally advanced/recurrent breast cancer
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2004-001749-13 Sponsor Protocol Number: P04071 Start Date*: 2005-02-22
    Sponsor Name:AESCA Pharma GesmbH
    Full Title: Randomized Phase II Study: Temozolomide (TMZ) Concomitant to Radiotherapy followed by sequential TMZ in Advanced NSCLC Patients with CNS Metastasis versus Radiotherapy alone
    Medical condition: Patients with non small cell lung cancer (NSCLC) have a high risk of developing brain metastasis, up to 40% as evaluated in autopsy studies. These patients are often heavily symptomatic and their l...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-013406-13 Sponsor Protocol Number: GBM-DC-2009 Start Date*: 2009-10-07
    Sponsor Name:Masaryk University
    Full Title: First Line Therapy of Glioblastoma Multiforme with Surgical Resection, Irradiation Therapy, Temozolomide and Additional Tumour-Lysate Pulsed Dendritic Cell Vaccination. A Feasibility Phase II Study...
    Medical condition: Glioblastoma Multiforme
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-000195-34 Sponsor Protocol Number: MO25616 Start Date*: 2011-06-21
    Sponsor Name:F. Hoffmann-La Roche Ltd.
    Full Title: A single arm, open-label, phase II, multicentre study to assess the safety of vismodegib (GDC-0449) in patients with locally advanced or metastatic basal cell carcinoma (BCC).
    Medical condition: Locally advanced or metastatic basal cell carcinoma (BCC)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10004146 Basal cell carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) AT (Completed) DE (Completed) BG (Completed) GB (Completed) BE (Completed) IT (Completed) ES (Completed) NL (Completed) SI (Completed) DK (Completed) HU (Completed) CZ (Completed) GR (Completed) SK (Completed) IE (Completed) PT (Completed) PL (Completed) NO (Completed) LT (Completed) FI (Completed) EE (Completed)
    Trial results: View results
    EudraCT Number: 2009-011445-13 Sponsor Protocol Number: IJB-BGDO-2009-001 Start Date*: 2009-11-26
    Sponsor Name:Institut Jules Bordet-Université Libre de Bruxelles
    Full Title: Preoperative chemosensitivity testing as Predictor of Treatment benefit in Adjuvant stage III colon cancer
    Medical condition: Stage III colon adenocarcinoma
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2008-001250-40 Sponsor Protocol Number: ICORG07-01 Start Date*: 2008-08-18
    Sponsor Name:Cancer Trials Ireland
    Full Title: An open-label Phase II Study of the Efficacy and Safety of the Combination of Fludarabine, Cyclophosphamide, And Rituximab in Patients with Chronic Lymphocytic Leukaemia who are Newly Diagnosed, ha...
    Medical condition: Chronic Lymphocytic Leukaemia
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008958 Chronic lymphocytic leukaemia PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IE (Completed)
    Trial results: View results
    EudraCT Number: 2009-016636-13 Sponsor Protocol Number: 113173 Start Date*: 2010-06-28
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: An open, dose-escalation Phase I/II study to assess the safety, immunogenicity and clinical activity of recPRAME + AS15 Antigen-Specific Cancer Immunotherapeutic as first-line treatment of patients...
    Medical condition: First-line treatment of patients with PRAME-positive unresectable stage III or IV metastatic melanoma
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004864 10027481 Metastatic melanoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2022-004130-19 Sponsor Protocol Number: CTRIAL-IE-22-04/NRG-HN009 Start Date*: 2023-05-24
    Sponsor Name:Cancer Trials Ireland
    Full Title: NRG-HN009: RANDOMIZED PHASE II/III TRIAL OF RADIATION WITH CISPLATIN AT 100 MG/M2 EVERY THREE WEEKS VERSUS RADIATION WITH WEEKLY CISPLATIN AT 40 MG/M2 FOR PATIENTS WITH LOCOREGIONALLY ADVANCED SQUA...
    Medical condition: Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN): Pathologically (histologically or cytologically) proven diagnosis of squamous cell carcinoma of the head and neck (SCC...
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041823 Squamous cell carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-003779-32 Sponsor Protocol Number: NL77171.091.21 Start Date*: 2021-09-27
    Sponsor Name:Radboud University Medical Center
    Full Title: HYPo-fractionated Radiotherapy of Lymph Node Metastases guided by NanO-MRI in Prostate Cancer Patients: A Pilot Study (HYPNO-study).
    Medical condition: men with biochemical recurrent prostate cancer after radical prostatectomy with ≤ 4 foci harbouring regional lymph node metastases (up to 6 lymph nodes in total) on nano-MRI.
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2004-002714-11 Sponsor Protocol Number: EORTC 22033-26033 Start Date*: 2005-06-06
    Sponsor Name:European Organisation for Research and Treatment of Cancer
    Full Title: Primary chemotherapy with temozolomide vs. radiotherapy in patients with low grade gliomas after stratification for genetic 1p loss: a phase III study
    Medical condition: Histologically proven low-grade glioma ♦ Astrocytoma WHO grade II (gemistocytic, fibrillary and protoplasmatic) ♦ Oligoastrocytoma WHO grade II ♦ Oligodendroglioma WHO grade II
    Disease: Version SOC Term Classification Code Term Level
    7.1 10025783 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) DE (Completed) GB (Completed) IT (Completed) DK (Prematurely Ended) BE (Completed) ES (Completed) PT (Completed) HU (Completed) SE (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2015-003130-27 Sponsor Protocol Number: 2015/2294 Start Date*: 2017-05-15
    Sponsor Name:Gustave Roussy
    Full Title: An international multicenter phase II randomized trial evaluating and comparing two intensification treatment strategies for metastatic neuroblastoma patients with a poor response to induction chem...
    Medical condition: Very High Risk neuroblastoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10008126 Cerebral neuroblastoma LLT
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: FR (Prematurely Ended) IT (Prematurely Ended) GB (GB - no longer in EU/EEA) ES (Prematurely Ended) NL (Completed) AT (Prematurely Ended) DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-002284-15 Sponsor Protocol Number: SSAT058 Start Date*: 2015-04-01
    Sponsor Name:St Stephen's AIDS Trust
    Full Title: SSAT058: A phase IV, open-label, multi centre pilot study to assess changes in cerebral function parameters in patients without perceived Central Nervous System (CNS) symptoms when switched from te...
    Medical condition: HIV
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2005-003931-40 Sponsor Protocol Number: BRD/05/95 Start Date*: 2006-04-20
    Sponsor Name:University College London
    Full Title: Phase ll Trial of Fludarabine & Cyclophosphamide followed by Thalidomide for Angioimmunoblastic Lymphoma
    Medical condition: Angioimmunoblastic T-cell lymphoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-005346-20 Sponsor Protocol Number: PA07/8376 Start Date*: 2007-12-04
    Sponsor Name:Leeds Teaching Hospitals NHS Trust
    Full Title: Does nebulised tobramycin (TOBI) via e-flow delivery systems cause a raised peak serum tobramycin level in children with Cystic Fibrosis?
    Medical condition: Children with cystic fibrosis
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2005-001173-96 Sponsor Protocol Number: PHOTOSTENT-02 Start Date*: 2005-10-26
    Sponsor Name:University College London
    Full Title: Porfimer sodium photodynamic therapy plus stenting versus stenting alone in patients with advanced or metastatic cholangiocarcinomas and other biliary tract tumours: a multicentre, randomised, phas...
    Medical condition: Advanced or metastatic cholangiocarcinomas and other biliary tract tumours
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-002808-34 Sponsor Protocol Number: 001 Start Date*: 2007-02-09
    Sponsor Name:St. Antonius Hospital
    Full Title: A phase II study of isolated lung perfusion with melphalan followed by pulmonary metastatectomy in patients with resectable pulmonary metastases of colorectal carcinoma, soft tissue sarcoma and ost...
    Medical condition: resectable pulmonary metastases of colorectal carcinoma, soft tissue sarcoma and osteosarcoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-003175-22 Sponsor Protocol Number: CCCC-H&N-IRT-1 Start Date*: 2018-08-02
    Sponsor Name:Charite Universitätsmedizin Berlin
    Full Title: Two-arm randomized phase II trial to assess the feasibility and efficacy of a treatment with Durvalumab a PDL1-Inhibitor plus Tremelimumab a CTLA-4- Inhibitor in combination with radiotherapy and a...
    Medical condition: NON-RESECTABLE LOCALLY ADVANCED HPV NEGATIVE HNSCC
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067821 Head and neck cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2021-005099-21 Sponsor Protocol Number: MER-XMT-1536-3 Start Date*: 2023-04-25
    Sponsor Name:Mersana Therapeutics, Inc.
    Full Title: A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Upifitamab Rilsodotin (XMT-1536) as Post-Platinum Maintenance Therapy for Participants with Recurrent, Platinum-Sensiti...
    Medical condition: Recurrent, Platinum-Sensitive Ovarian Cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066697 Ovarian cancer recurrent PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FR (Completed) NO (Prematurely Ended) DE (Prematurely Ended) AT (Prematurely Ended) IT (Prematurely Ended) SE (Prematurely Ended) ES (Prematurely Ended) DK (Prematurely Ended) BE (Prematurely Ended) NL (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Jul 05 01:55:14 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA